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The influence of Green Coffee Bean Extract Supplementation on Blood Glucose Levels: A 
Systematic Review and Meta-Analysis of Randomized Controlled Trials 
Abstract 
Aims
Studies regarding the influence of Green Coffee Extract (GCE) on blood glucose levels are
conflicting. Thus, we sought to conduct a meta-analysis and systematic review of all available
randomized controlled trials (RCTs) to quantify the effects of GCE and CGA intervention on blood 
glucose and insulin levels.
Methods 
We performed systematic online searches in Scopus, Web of science, and PubMed databases, from
inception to July 2019. Data were combined analyzed using a random effects model (Der
Simonian-Laird method), and reported as weighted mean differences (WMD). Ten trials reported
the influences of GCE on FBS and insulin, and were subsequently entered into the meta-analysis. 
Results 
Combined results highlighted that FBS was significantly altered after GCE consumption (WMD:
-1.791mg/dl,95% CI:-3.404,-0.177), with no significant heterogeneity among the studies
(I2=35.0%,p=0.128). However, overall results demonstrated that GCE administration did not
result in any significant alteration in insulin levels (WMD: -0.925 μU/ml,95% CI:-1.915,0.064),
with significant heterogeneity found across studies (I2 =87.9 %). In sub-group analysis, insulin







    






      
   
      
    
       
       
   
   
    
 
         
      
       
     
    
    
     
    
The results of present study support the use of GCE for the enhancement of blood glucose, whilst 
sub-group analysis highlighted significant improvements in insulin levels when GCE is
supplemented in doses ≥400mg/d. 
Keywords: Green coffee, insulin, FBS, blood glucose
Introduction
Contemporary evidence suggests that high blood glucose concentration is associated with chronic 
disease onset in patients with prediabetes or diabetes (Rizza, 2010; Standl, Schnell, & Ceriello, 
2011). Therefore, reducing elevated blood glucose concentrations is a principal aim in the
amelioration and management of chronic metabolic disorders (Rizza, 2010). Postprandial
hyperglycemia is a prominent risk factor for metabolic syndrome (Adeyemi et al., 2017); although
medicinal therapeutic strategies, such as insulin and hypoglycemic drugs, have accomplished some 
success in treatment, pharmacological interventions possess well-known adverse side effects 
(Scheen, 2005). Thus, recent investigations have focused on nonpharmacologic approaches to
reduce blood glucose levels (Chikwere & Annan, 2016; Iddrisu, Oduro, Tandoh, & Annan, 2015; 
O’Keefe, Gheewala, & O’Keefe, 2008). 
One of the most frequently consumed beverages in the world is coffee (Shang, Li, & Jiang, 2016). 
It is a major source of bioactive components, including phenolic acids, methylxanthines, and 
particularly polyphenol compounds, that are well-known as protective agents against numerous
chronic degenerative diseases (Esquivel & Jiménez, 2012; Gaafar, El-Ghamery, & Mahmuod,
2013). Various epidemiological and in vivo (experimental) examinations have demonstrated an 
inverse relationship between coffee ingestion and risk of several glycemic indicators of diabetes 
mellitus (DM) (Greenberg, Boozer, & Geliebter, 2006; Tanaka et al., 2009), and a positive link





      
      
      
     
     
      
   
    
       
       
     
   
       
      
    
    
  
   
     
     




compound in coffee beans is regarded to be Chlorogenic Acid (CGA), given that numerous
favorable health effects are derived from it (Ong, Hsu, & Tan, 2012). In fact, CGA is recognized 
as a family a esters formed from quinic acid and cinnamic acids, especially p-coumaric, ferulic
and caffeic acids, that posses several biological features, such as antioxidant, anti-bacterial, and
anti-carcinogenic characteristics (M. Clifford, 1985). Green Coffee Extract (GCE) has a high
amount of polyphenol compounds and is a rich source of CGA (M. N. Clifford, 1999); indeed, 
recent human studies have revealed that GCE and CGA supplementation can yield reductions in 
insulin resistance and blood glucose concentrations (Thom, 2007). Various mechanisms have been
posited for the impact of GCE/CGA on glucose metabolism, however, the precise mechanism
remains unclear. One proposed mechanism is a reduction in the process of intestinal glucose uptake
by regulating levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide-I (GLP-I), which elevates insulin secretion after oral glucose ingestion (Johnston, Clifford, 
& Morgan, 2003). In addition, CGA, by decreasing glucose-6-phosphatase enzyme activity, can
reduce the process of gluconeogenesis and glycogenolysis, respectively (Hemmerle et al., 1997). 
However, the exact effect of GCE and CGA on glycemic indicators levels is largely unclear, and
previous clinical trials have reported controversial results; indeed, several studies have shown GCE 
supplementation leads to decrements in blood glucose and insulin concentrations (Hanieh Roshan,
Omid Nikpayam, Meghdad Sedaghat, & Golbon Sohrab, 2018; Satoko Soga, Noriyasu Ota, &
Akira Shimotoyodome, 2013), whilst contrastingly, some trials do not support these results 
(Satoko Fukagawa et al., 2017; Takuya Watanabe et al., 2006). Thus, we sought to conduct a meta-
analysis and systematic review of all available randomized controlled trials (RCTs) to quantify the






     
      
 
 
    
        
      
   
      
       
    
 
      
       
      
        
        
     
      
 
 
     
    
  
This article was carried out in accordance with the Preferred Reporting Items for a Systematic
Review and Meta-analysis guidelines (Guyatt et al., 2008; McInnes et al., 2018). This study was
not prospectively registered.
Search strategy
We performed systematic online searches in the online databases, Scopus, Web of science, and 
PubMed, from inception to July 2019. The following search words were used: "green coffee" OR
"chlorogenic acid" OR "green coffee extract" AND "clinical trials " OR "double-blind method OR 
"cross-over studies" OR "single-blind method" OR RCT OR "random allocation" OR "intervention 
studies" OR "controlled trial" OR "intervention" OR "randomized" OR "randomised" OR
"randomly" "random" OR "assignment" OR "placebo". We also reviewed the reference lists of 
previous reviews to detect potentially eligible publications.
Eligibility criteria
Two authors independently implemented the initial examination. Any discrepancy was resolved
by conversation and consensus by the lead author. To be eligible, studies had to meet the ollowing
criteria: (1) Population: adult subjects more than 18 years. (2) Intervention: green coffee extract 
supplementation. (3) Comparison: placebo group. (4) Primary outcomes: articles that report
adequate information (mean and SD) on baseline and final study of FBS or insulin in both GCE
and placebo groups. The most recent data were used for duplicates. Comments, reviews, letters, 
experimental study, and animal studies were excluded. Trials with unobtainable data were also 
excluded.
Data extraction
Two investigators individually executed the information extraction using a standard excel sheet.
Any discrepancy was resolved by consensus with the lead author. Subsequently, the following 








        
   
   
        
          
           
     
 
 
       
     
         
        
   
    
           
             
     
      
      
   
or insulin levels, intervention versus comparison, doses for GCE, treatment period (week). We
also emailed the corresponding authors to acquire the data, if required. 
Quality assessment
We applied the Cochrane risk of bias tool to evaluate the quality of eligible publications (J. P. 
Higgins et al., 2011). This assessment tool comprises of random sequence generation, allocation
concealment, blinding of subjects, personnel-to-study protocol, blinding of results assessment, 
incomplete outcomes data, selective reporting, and other bias. The trials were assortment as high
risk, low risk, and unclear risk of bias based on the reported items. Trials with more than one key
criterion was recorded as possessing a high risk of bias, those without all items were regarded as 
possessing a low risk of bias. Otherwise, they were defined as having an unclear risk of bias.
Statistical methods
We combined data using the generic inverse variance approach, with random effects model (using 
DerSimonian-Laird approach), and reported as weighted mean differences (WMDs) with 95%
confidence intervals (CIs). We used Stata program (Stata Corp. College Station, Texas, USA) for
primary analyses, sensitivity analyses, and publication bias and dose response analyses. We used
standard calculations to obtain the mean and SD when data was expressed in a different format (J.
Higgins, 2011; Hozo, Djulbegovic, & Hozo, 2005). For instance, if the SD of the change was not 
expressed in the trials, we derived it using the following formula: SD differences = square root 
[(SD baseline 
2+SD end 
2) - (2×R× SD baseline× SD end)]. We assessed heterogeneity across studies by
the Cochran Q statistic and quantified using the I2 statistic. We explored sources of heterogeneity
by stratified analyses and sensitivity analyses, in which each study was excluded separately, and 
the overall effect size re-estimated. Publication bias was measured by means of Egger’s tests and 










   
       
      




    
  
  
   
          
       
      
   
     
        
   
 
    
method was applied to assess the number of omitted publications due to publication bias (Palmer,
Peters, Sutton, & Moreno, 2008).
Results
Study selection
The initial database search yielded 831 records; following elimination of duplictes,646 
publications remained. In the next step, all articles’ abstract and titles were screened, which
resulted in 24 papers for full-manuscript examination. Ultimately, 10 publications were included
in this study. Of the 10 eligible articles, all 10 trials reported the influences of GCE on FBS (S. 
Fukagawa et al., 2017; Haidari, Samadi, Mohammadshahi, Jalali, & Engali, 2017; Kim et al., 2012; 
Ochiai et al., 2004; Park, Kim, Lee, & Lee, 2010; H. Roshan, O. Nikpayam, M. Sedaghat, & G. 
Sohrab, 2018; Shahmohammadi, Hosseini, Hajiani, Malehi, & Alipour, 2017; S. Soga, N. Ota, & 
A. Shimotoyodome, 2013; Suzuki et al., 2019; T. Watanabe et al., 2006), and 5 trials reported on
insulin (S. Fukagawa et al., 2017; Haidari et al., 2017; Park et al., 2010; H. Roshan et al., 2018;
Shahmohammadi et al., 2017) (Figure 1).
Characteristics of the eligible trials
The characteristics of the eligible trials are detailed in Table 1. Included papers were published
between 2004 and 2019., and were conducted in different countries; including, three in the Iran
(Haidari et al., 2017; H. Roshan et al., 2018; Shahmohammadi et al., 2017), five in Japan (S. 
Fukagawa et al., 2017; Ochiai et al., 2004; S. Soga et al., 2013; Suzuki et al., 2019; T. Watanabe
et al., 2006), and two in Korea (Kim et al., 2012; Park et al., 2010). The treatment duration varied
between 2 and 16 weeks, whilst daily administrated dosage of GCE ranged from 100 to 1000 mg.
Studies were conducted on both genders (H. Roshan et al., 2018; Shahmohammadi et al., 2017; T. 
Watanabe et al., 2006), on men (Ochiai et al., 2004; S. Soga et al., 2013; Suzuki et al., 2019), and





       
        
      
     
     
 
  
    
        
     
   
 
 
   
             
         
     
        
    
  
     
       
       
  
 
The participant number in the studies ranged from 16 to 64, whilst the study population in eligible
publications consisted of; adults with mild hypertension (T. Watanabe et al., 2006), adults with
 
the metabolic syndrome (H. Roshan et al., 2018) and adults with NAFLD (Non-Alcoholic Fatty
 
Liver Disease) (Shahmohammadi et al., 2017), adults who were classified as obese or overweight
 
(Haidari et al., 2017; Kim et al., 2012; Park et al., 2010), or healthy individuals (S. Fukagawa et 

al., 2017; Ochiai et al., 2004; S. Soga et al., 2013; Suzuki et al., 2019).
 
Quality assessment of eligible studies
 
Risk of bias and methodological quality of eligible trials are reported in Supplemental Table 1.
 
Breifly, trials indicated acceptable quality for key items; hilst incomplete outcome data (S.
 
Fukagawa et al., 2017; Haidari et al., 2017) and allocation concealment items (Haidari et al., 2017)
 
were the main sources of bias.
 
Meta-analysis results
Impact of green coffee extract administration on FBS
Ten arms, with 363 subjects (case=179, and control=184), described FBS as an outcome measure.
Overall results demonstrated that FBS was significantly altered after green coffee extract 
consumption (WMD: -1.791mg/dl, 95% CI: -3.404, -0.177, p = 0.030), with no significant
heterogeneity across the trials (I2 = 35.0%, p = 0.128) (Figure2). In subgroup analyses, FBS was 
significantly reduced in the subgroup in green coffee extract supplementation dosages of ˂400 
mg/day (WMD: -1.21 mg/dl, 95% CI: -2.40, -0.02, p<0.001; I2 = 1.7 %). In addition, in treatment
durations ≤ 8weeks (WMD: -1.94 mg/dl, 95% CI: -3.82, -0.06), there was a greater reduction in
FBS compared with treatment durations ˃ 8 weeks(WMD: -0.99 mg/dl, 95% CI: -5.77, 3.88)
(Supplemental Figure 1).. However, the number of studies in some subgroups was low, and the





    
 
    
        
       
       
      
  
    
         
    
      
  
      
      
     
 
       
      
    
 
      
    
  
 
(Supplemental Figure 1). 
Impact of green coffee extract administration on insulin levels
Five arms, with 243 subjects (case=119, and control=124), reported IN as an outcome measure.
Pooled results revealed that green coffee extract administration did not result in any significant
modification in insulin (WMD: -0.925 μU/ml, 95% CI: -1.915, 0.064, p = 0.067). We observed
significant heterogeneity among trials (I2 = 87.9 %, p<0.001) (Figure2). Results of the subgroup 
analyses showed that green coffee extract dosage (mg/day) was a source of heterogeneity. In sub­
group analysis, insulin levels were significantly reduced in green coffee extract supplementation
dosages of ≥400 mg/day (WMD: -1.942 mg/dl, 95% CI: -1.184, -0.975, p<0.001; I2 = 0.0 %, p =
0.492) (Supplemental Figure 1). 
Non-linear dose-responses relationship between dose of green coffee extract and treatment
duration and outcomes
Figure 4 depicts the results of the non-linear dose-response meta-analysis. The results highlighted
that green coffee extract intake significantly alters FBS based on follow up duration (Coef. = ­
1.84, p= 0.016) or green coffee dosage (Coef. = -2.90, p= 0.044).
Sensitivity analysis
To ascertain the influence of each single trial on the meta-analyses, we excluded each arm from 
overall effect size, step by step. No significant impact of any individual study was observed on the 
coverall effect sizes of FBS, and insulin levels (Supplemental Figure 2).
Publication bias
Visual inspection of funnel plot established no evidence of publication bias in the present study
(Figure5). Egger’s linear regression test also confirmed the funnel plot conclusion (FBS: p=0.160, 






     
      
     
     
  
  
       
     
      
  
    
      
      
     
  
  
    
     
    
  
        
   
     
     
    
Contemporary evidence suggests that high blood glucose concentrations in humans are
inextricably linked with chronic disease onset in patients with prediabetes or diabetes (Rizza, 2010;
Standl et al., 2011), and as such, reducing or managing blood glucose concentrations represents an
overarching aim in the amelioration and management of chronic metabolic disorders (Rizza,
2010). Traditional medicinal, therapeutic strategies, such as insulin and hypoglycemic drugs have
achieved some success in managing high blood glucose, however, pharmacological interventions
have well-known, adverse side effects (Scheen, 2005). Recently, bioactive phytochemicals of
coffee have gained eminence because of their biological properties, including; anti-inflammatory
and antioxidant activities (Godos et al., 2014), augmented insulin sensitivity and fatty acid 
oxidation, and modulation of glucose utilization and absorption (Sudeep, Venkatakrishna, Patel, 
& Shyamprasad, 2016). Whilst recently, Gorji et al, in a comprehensive meta-analysis, supported 
the use of GCE for the enhancement of obesity indices, with stratified analysis highlighting more
enhancements in participants with a baseline BMI ≥25kg/m2 (Gorji et al., 2019). However,
regarding the effect of GCE and CGA on glycemic indicators levels, there remains a dearth of 
consensus. Several studies have shown GCE supplementation decreased blood glucose and insulin 
concentrations (Hanieh Roshan et al., 2018; Satoko Soga et al., 2013), whilst contrastingly, an
equivalent number of trials did not support such assertions (Satoko Fukagawa et al., 2017; Takuya
Watanabe et al., 2006). Moreover, previously published reviews have few studies, and did not
evaluate the effects of CGA and GCE supplementation on blood glucose and insulin levels in a 
dose response model (Faraji, 2018; Nikpayam et al., 2019). Thus, our aim was to perform a dose-
responses meta-analysis and systematic review of all published RCTs to quantify the effects of
CGA and GCE supplementation on blood glucose and insulin levels In accord with the 
aforementioned aim, overall results specified that GCE did not result in any significant alteration
in IN, however, sub-group analysis highlighted that IN was significantly reduced when GCE was





       
 
       
  
      
    
  
       
       
    
   
    
   
      
   
            
          
   
      
        
     
     
 
 
reduced following GCE consumption, and responded in a non-linear fashion with GCE dosage and
treatment duration, respectively.
Coffee is a major source of bioactive components, including methylxanthines, phenolic acids, and, 
in particular, polyphenol compounds (Esquivel & Jiménez, 2012; Gaafar et al., 2013). Chlorogenic 
acids (ester of caffeic acid and quinic acid) is the glycosylated derivate forms of polyphenol, the
major polyphenol exist in coffee. Polyphenols have repeatedly been shown to combat non­
communicable diseases related with oxidative stress and its incumbent complications (Manach, 
Scalbert, Morand, Rémésy, & Jiménez, 2004). There exists agglomerative evidence that coffee can
elicit positive changes in metabolic syndromes such as type 2 diabetes, obesity, and insulin-
resistance (Dickson et al., 2015; Ding, Bhupathiraju, Chen, van Dam, & Hu, 2014; Ho et al., 2012;
Salamat et al., 2019). Numerous different pharmacological publications regarding GCE reported
that the chlorogenic acids constituent in GCE can regulate hypertension, glucose metabolism, and
vasoreactivity (Blum, Lemaire, & Lafay, 2007; Kozuma, Tsuchiya, Kohori, Hase, & Tokimitsu, 
2005). Indeed, in the current meta analyses we demonstrated that FBS is significantly reduced
following GCE consumption, and the response is not dependent on dosage or duration of treatment. 
Previous results suggest that any protective impacts of coffee are unlikely to be specially
attributable to caffeine, but rather, as speculated earlier, they likely involve a broader range of
chemical constituents, such as magnesium(Haytowitz et al., 2011), lignans (Milder, Arts, van de
Putte, Venema, & Hollman, 2005) and chlorogenic acids (M. N. Clifford, 1999). The impacts of 
these coffee constituents on glucose metabolism and insulin sensitivity from both animal studies
and in vitro experiments have been extensively reviewed (Van Dam, 2006), and, indeed, in the







       
     
    
     
      
         
     
        
          
      
         
   
     
          
       
  
   
          
   
       
    
      
     
       
   
Diets abundant in polyphenols may be conducive to the prevention of numerous diseases or
comorbidities related with oxidative stress, such as coronary heart disease and various cancers
(Adlercreutz & Mazur, 1997; Tijburg, Mattern, Folts, Weisgerber, & Katan, 1997). Green coffee
extract has been demonstrated efficient of scavenging free radicals in vitro, whilst yielding 
increases in the antioxidant ability of plasma, in vivo (Blum et al., 2007; Monteiro, Farah, Perrone,
Trugo, & Donangelo, 2007). Moreover, there is empirical data available to suggest that GCE,
might mediate intestinal glucose absorption (Bidel, Hu, Sundvall, Kaprio, & Tuomilehto, 2006; 
Lopez-Garcia et al., 2006). This biological activity may present a basis for putatively elucidation 
its impacts on FBS and IN, where GCE would have a protective impact against diabetes via
modifications in gastrointestinal hormone secretion (Greenberg et al., 2006). Additionally, the
mechanism by which blood glucose may be declined by chlorogenic acids is reputedly via its 
stimulation of AMP-activated protein kinase (AMPK). Stimulation of AMPK contributes to the 
improvement of GLUT4 translocation to the plasma membrane, amplifying transportation of 
glucose to the cells, leading to peripheral glucose disposal (Ong et al., 2012). With particular
reference to chlorogenic acids, which are highly abundant in GCE, they are, independently, 
asserted to elicit positive effects on type 1 diabetes, blood glucose and insulin sensitivity via their 
antioxidant properties(M. N. Clifford, 1999), effects on soft tissue mineral composition through
action as a metal chelator (de Sotillo & Hadley, 2002), decreasing of hepatic glucose output
through inhibition of glucose-6-phosphatase (Arion et al., 1997; Herling et al., 1999), and
declining of intestinal glucose uptake through inhibition of glucose-6-phosphate translocase 1 and
other mechanisms, and a subsequent elevate in GLP-1 (McCarty, 2005). Given the putative 
mechanisms above, it is conceivable that the significant alterations to IN are only manifest in 
dosages >400mg/d because modifications in gastrointestinal hormone secretion might only be
viable at higher quantities (Greenberg et al., 2006). Furthermore, some evidence suggests that GCE 






     
  
 
     
   
    
         
      
     
     
      
      
       
    
 
       
     
   
  
       
   
      
  
higher quantities (Bidel, Hu, Sundvall, Kaprio, & Tuomilehto, 2006; Lopez-Garcia et al., 2006). 
Notwithstanding, however, the above explanation for the dose-response found in this study is
speculative, and clearly necessitates detailed, mechanistic work.
Strength and limitations
The most important strength of this study was that this meta-analysis reported a 
comprehensive overview of the impact of GCE on blood glucose as manifest in human-based 
RCTs; and specified the potential to treat or manage blood glucose dysfunction or disease, this is
valuable endeavor. The evidence base, previous to present meta-analysis, was distinctly lacking in
consensus, and thus, immediately required a quantitative assessment, summative, which we have
reported. Indeed, systematic reviews and meta-analyses are at the top in the hierarchy of the
clinical evidence (Colato). We revealed that there is adequate evidence for GCE administration to
elicit positive impacts on FBS, and insulin levels (when consumed in doses ≥400mg/d). A Further
strength of the present study is the assimilation of the heterogeneous sample of individuals, with a
range of ages and ethnicities. We were also able to stratify analyses across both duration of 
intervention and dose, therein providing foresight into expected results based on such data, and of 
particular interest is that FBS responded in a non-linear fashion.
Notwithstanding, the present study has some limitations. The analyses enabled a larger
number of trials and individuals to be included for meta-analyses, however could possibly impact
mechanism of effectiveness and action, and thus warrants further investigation. Furthermore, due
to lack of rigorous regulation, there is a distinct need for the manufacturers of GCE products to 
prove efficacy, safety and quality of a marketed product, particularly given such concerns are less
strongly enforced than in the pharmaceutical sector (Williamson), which may have influenced the 
emergence of significant heterogeneity among included studies. Moreover, many available






                 
     
        
       
       
     
      
   
     
 
 

















The results of the present meta-analysis study confirm the use of GCE administration for
the enhancement of blood glucose, where FBS was improved, and sub-group analysis highlighted
improvement in insulin levels when consumed is doses ≥400mg/d. We have highlighted the
positive impact elicited by GCE intervention for some clinically relevant variables (FBS and
insulin levels), however, it is manifested that more, well-controlled and randomized trials are
required to support the veracity of our findings, and importantly, and, in particular, explicate the
mechanism in population and health status sub-groups. Furthermore, there is the possibility that
studies discussed in the present review article have not been performed in accordance with a recent 
consensus document providing a perspective in best practice in pharmacological research on
bioactive preparations from plants (Heinrich et al).
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